Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147613 | 0.87 | KDM4A (0.38) | KDM4ERAB9AMEN1KMT2ABCHE | |
| SCHEMBL1694902 | 0.81 | KDM4E (0.40) | KDM4EMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1694665 | 0.81 | KMT2A (0.42) | KDM4ERAB9AMEN1KMT2AHTT | |
| SCHEMBL1695356 | 0.77 | KDM4E (0.40) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL10146902 | 0.72 | PIK3CD (0.38) | — | |
| SCHEMBL1694796 | 0.70 | TLR8 (0.36) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10147609 | 0.68 | PARP1 (0.41) | RAB9AMEN1KMT2ABCHE | |
| SCHEMBL24596021 | 0.67 | SMN1; SMN2 (0.47) | KDM4ERAB9AMEN1KMT2APOLB | |
| SCHEMBL24951562 | 0.67 | KDM4E (0.47) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31133550 | 0.67 | KDM4E (0.47) | KDM4EL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | KDM4E 1440/4885RAB9A 3087/4885MEN1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.